| Adhesion molecules in multiple myeloma oncogenesis and targeted therapy M Bou Zerdan, L Nasr, J Kassab, L Saba, M Ghossein, M Yaghi, ... International Journal of Hematologic Oncology 11 (2), IJH39, 2022 | 21 | 2022 |
| A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents NJ Short, M Muftuoglu, F Ong, L Nasr, W Macaron, G Montalban-Bravo, ... Journal of Hematology & Oncology 16 (1), 73, 2023 | 11 | 2023 |
| Impact of ABO and Rhesus blood groups on COVID‐19 susceptibility and severity: A case‐control study A Kerbage, SF Haddad, L Nasr, A Riachy, E Mekhael, N Nassim, K Hoyek, ... Journal of Medical Virology 94 (3), 1162-1166, 2022 | 11 | 2022 |
| Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML NJ Short, N Daver, CD Dinardo, T Kadia, LF Nasr, W Macaron, M Yilmaz, ... Journal of Clinical Oncology, JCO. 23.01911, 2024 | 8 | 2024 |
| AI-based online chat and the future of oncology care: a promising technology or a solution in search of a problem? J Kassab, L Nasr, G Gebrael, M Chedid El Helou, L Saba, E Haroun, ... Frontiers in Oncology 13, 1176617, 2023 | 8 | 2023 |
| Systemic AL amyloidosis: current approach and future direction MB Zerdan, L Nasr, F Khalid, S Allam, Y Bouferraa, S Batool, M Tayyeb, ... Oncotarget 14, 384, 2023 | 8 | 2023 |
| Central nervous system prophylaxis and treatment in acute leukemias SY Wu, NJ Short, L Nasr, BS Dabaja, PQ Fang Current treatment options in oncology 23 (12), 1829-1844, 2022 | 7 | 2022 |
| Lebanese real-world experience in treating multiple myeloma: A multicenter retrospective study F Nasr, A Al Ghoche, S Diab, L Nasr, E Ammanouil, C Riachy, S Hallit, ... Leukemia Research Reports 15, 100252, 2021 | 7 | 2021 |
| P485: Azacitidine, venetoclax and gilteritinib for patients with newly diagnosed flt3-mutated acute myeloid leukemia: A subgroup analysis from a phase ii study N Short, W Macaron, C Dinardo, N Daver, M Yilmaz, G Borthakur, ... HemaSphere 7 (S3), e535260f, 2023 | 6 | 2023 |
| A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic … NJ Short, E Jabbour, N Jain, F Haddad, W Macaron, M Yilmaz, A Ferrajoli, ... Journal of Clinical Oncology 41 (16_suppl), e19017-e19017, 2023 | 4 | 2023 |
| A synopsis clonal hematopoiesis of indeterminate potential in hematology M Bou Zerdan, L Nasr, L Saba, P Meouchy, N Safi, S Allam, J Bhandari, ... Cancers 14 (15), 3663, 2022 | 4 | 2022 |
| S119: COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA … F Haddad, E Jabbour, C Nasnas, N Short, W Macaron, M Zoghbi, L Nasr, ... HemaSphere 7, e89468e9, 2023 | 3 | 2023 |
| Updated Results from a Phase II Study of Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute … D Nguyen, HM Kantarjian, NJ Short, N Jain, FG Haddad, M Yilmaz, ... Blood 142, 4245, 2023 | 2 | 2023 |
| A Phase II Study of Low-Intensity Chemotherapy (Mini-Hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive Acute … WY Jen, E Jabbour, FG Haddad, L Nasr, NJ Short, M Zoghbi, C Nasnas, ... Blood 142, 2868, 2023 | 2 | 2023 |
| Phase 2 Trial of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute … WY Jen, E Jabbour, FG Haddad, NJ Short, N Jain, TM Kadia, N Daver, ... Blood 142, 2878, 2023 | 2 | 2023 |
| P358: hyper-CVAD with blinatumomab and inotuzumab ozogamicin for patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia: a phase II … N Short, E Jabbour, N Jain, F Haddad, M Yilmaz, L Nasr, A Ferrajoli, ... HemaSphere 7 (S3), e67564ca, 2023 | 2 | 2023 |
| S118: A Chemotherapy-Free Combination of Ponatinib and Blinatumomab For Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Subgroup … N Short, E Jabbour, N Jain, X Huang, W Macaron, L Nasr, ... HemaSphere 7 (S3), e4968152, 2023 | 2 | 2023 |
| A phase II trial of ponatinib and blinatumomab in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). NJ Short, E Jabbour, N Jain, W Macaron, X Huang, G Montalban-Bravo, ... Journal of Clinical Oncology 41 (16_suppl), e19013-e19013, 2023 | 2 | 2023 |
| Dose-dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab achieves Rapid MRD-Negativity in Philadelphia chromosome-negative B-cell Acute Lymphoblastic Leukemia NJ Short, E Jabbour, T Jamison, S Paul, B Cuglievan, D McCall, A Gibson, ... Clinical Lymphoma Myeloma and Leukemia 24 (4), e168-e173, 2024 | 1 | 2024 |
| Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL Y Zhao, NJ Short, HM Kantarjian, TC Chang, PS Ghate, C Qu, W Macaron, ... Blood Journal, blood. 2024023930, 2024 | 1 | 2024 |
Nicholas J. ShortAssociate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer CenterVerified email at mdanderson.org
